Fruquintinib for previously treated metastatic colorectal cancer

Published on 04 Jun 2025
Last Updated on 16 Sep 2025

Guidance Recommendations

The Ministry of Health’s Drug Advisory Committee has recommended:

• Fruquintinib 1 mg and 5 mg capsules for treating patients with metastatic colorectal cancer who have been previously treated with, or are not considered candidates for, available therapies including fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy, anti-VEGF therapy, and if RAS wild-type, anti-EGFR therapy.

Funding status

Fruquintinib 1 mg and 5 mg capsules are recommended for inclusion on the Medication Assistance Fund (MAF) for the abovementioned indication from 1 November 2025.

Clinical indication, subsidy class and MediShield Life claim limit for fruquintinib are provided in the Annex.

Fruquintinib for previously treated metastatic colorectal cancer (Updated 16 Sep 2025)